Acute myeloid leukemia arising from previous myelodysplastic syndrome
Clinical trials for Acute myeloid leukemia arising from previous myelodysplastic syndrome explained in plain language.
Never miss a new study
Get alerted when new Acute myeloid leukemia arising from previous myelodysplastic syndrome trials appear
Sign up with your email to follow new studies for Acute myeloid leukemia arising from previous myelodysplastic syndrome, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a cancer drug help patients with rare gene changes?
Disease control OngoingThis phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New chemo combo aims to stop leukemia return after transplant
Disease control OngoingThis phase 2 trial tests giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant in 72 patients with leukemia or myelodysplastic syndrome in remission. The goal is to prevent the cancer from coming back after the transplant while causing fewe…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo shows promise for MDS and AML
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough blood cancer in seniors
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a targeted drug boost chemo for hard-to-treat blood cancers?
Disease control OngoingThis phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy boosts chemo to wipe out hidden leukemia cells
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shows promise in early AML trial
Disease control OngoingThis early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 1/2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Talking therapy tackles tiredness in blood cancer patients
Symptom relief OngoingThis study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC